Atrys Health SL Net Assets
Atrys Health SL net assets. Based on the latest financial reports, Atrys Health SL (ATRY) has net assets worth €147.49 Million EUR (≈ $172.43 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€315.60 Million ≈ $368.97 Million USD) and total liabilities (€168.11 Million ≈ $196.53 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Atrys Health SL to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €147.49 Million |
| % of Total Assets | 46.73% |
| Annual Growth Rate | 28.13% |
| 5-Year Change | -44.54% |
| 10-Year Change | 965.38% |
| Growth Volatility | 73.11 |
Net Assets of Atrys Health SL (2012–2025)
Net assets of Atrys Health SL from 2012 to 2025. This chart illustrates how Atrys Health SL's net assets have evolved over time, based on quarterly financial data. See Atrys Health SL (ATRY) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Atrys Health SL (2012–2025)
The table below shows the annual net assets of Atrys Health SL from 2012 to 2025. For live market cap and overall valuation, see Atrys Health SL market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €151.96 Million ≈ $177.65 Million |
-40.00% |
| 2024-12-31 | €253.24 Million ≈ $296.07 Million |
-12.64% |
| 2023-12-31 | €289.88 Million ≈ $338.90 Million |
-14.13% |
| 2022-12-31 | €337.57 Million ≈ $394.66 Million |
+23.21% |
| 2021-12-31 | €273.98 Million ≈ $320.31 Million |
+263.72% |
| 2020-12-31 | €75.33 Million ≈ $88.07 Million |
+88.53% |
| 2019-12-31 | €39.95 Million ≈ $46.71 Million |
+51.10% |
| 2018-12-31 | €26.44 Million ≈ $30.91 Million |
+13.50% |
| 2017-12-31 | €23.30 Million ≈ $27.24 Million |
+63.34% |
| 2016-12-31 | €14.26 Million ≈ $16.68 Million |
+21.91% |
| 2015-12-31 | €11.70 Million ≈ $13.68 Million |
+69.04% |
| 2014-12-31 | €6.92 Million ≈ $8.09 Million |
+4.58% |
| 2013-12-31 | €6.62 Million ≈ $7.74 Million |
+9.26% |
| 2012-12-31 | €6.06 Million ≈ $7.08 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Atrys Health SL's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14810.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Atrys Health SL Net Assets Breakdown (December 2025)
Atrys Health SL net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €760.00K | 0.50% |
| Other Comprehensive Income | €-268.64 Million | -176.90% |
| Other Components | €520.03 Million | 342.44% |
| Total Equity | €151.86 Million | 100.00% |
Atrys Health SL Competitors by Market Cap
The table below lists competitors of Atrys Health SL ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lightron Inc.
KQ:069540
|
$205.01 Million |
|
Kalekim Kimyevi Maddeler Sanayi & Ticaret AS
IS:KLKIM
|
$205.03 Million |
|
Grupo Hotelero Santa Fe SAB
MX:HOTEL
|
$205.10 Million |
|
Mastersystem Infotama Tbk.
JK:MSTI
|
$205.11 Million |
|
Garanti Faktoring AS
IS:GARFA
|
$204.95 Million |
|
Caregen Co.Ltd
KQ:214370
|
$204.94 Million |
|
Politeknik Metal Sanayi ve
IS:POLTK
|
$204.94 Million |
|
Sekerbank TAS
IS:SKBNK
|
$204.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Atrys Health SL's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 253,098,000 to 151,860,000, a change of -101,238,000 (-40.0%).
- Net loss of 100,296,000 reduced equity.
- Share repurchases of 36,000 reduced equity.
- Other comprehensive income decreased equity by 101,243,999.
- Other factors increased equity by 100,337,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-100.30 Million | -66.05% |
| Share Repurchases | €36.00K | -0.02% |
| Other Comprehensive Income | €-101.24 Million | -66.67% |
| Other Changes | €100.34 Million | +66.07% |
| Total Change | €- | -40.00% |
Book Value vs Market Value Analysis
This analysis compares Atrys Health SL's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.33x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.55x to 1.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | €0.75 | €2.65 | x |
| 2013-12-31 | €0.82 | €2.65 | x |
| 2014-12-31 | €0.85 | €2.65 | x |
| 2015-12-31 | €1.27 | €2.65 | x |
| 2016-12-31 | €1.31 | €2.65 | x |
| 2017-12-31 | €2.14 | €2.65 | x |
| 2018-12-31 | €1.36 | €2.65 | x |
| 2019-12-31 | €1.86 | €2.65 | x |
| 2020-12-31 | €2.52 | €2.65 | x |
| 2021-12-31 | €5.12 | €2.65 | x |
| 2022-12-31 | €4.95 | €2.65 | x |
| 2023-12-31 | €3.82 | €2.65 | x |
| 2024-12-31 | €3.35 | €2.65 | x |
| 2025-12-31 | €2.00 | €2.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Atrys Health SL utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -66.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -71.13%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 3.25x
- Recent ROE (-66.05%) is below the historical average (-5.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 11.26% | 63.17% | 0.06x | 3.02x | €76.06K |
| 2013 | 5.08% | 33.03% | 0.05x | 2.85x | €-325.28K |
| 2014 | 4.63% | 29.39% | 0.06x | 2.82x | €-371.90K |
| 2015 | 12.59% | 45.18% | 0.11x | 2.54x | €266.07K |
| 2016 | 0.44% | 1.06% | 0.20x | 2.14x | €-1.36 Million |
| 2017 | 1.25% | 3.62% | 0.20x | 1.73x | €-2.04 Million |
| 2018 | 0.05% | 0.16% | 0.14x | 2.03x | €-2.63 Million |
| 2019 | -0.26% | -0.71% | 0.17x | 2.20x | €-4.10 Million |
| 2020 | -7.77% | -16.41% | 0.19x | 2.46x | €-12.69 Million |
| 2021 | -8.47% | -19.17% | 0.21x | 2.06x | €-50.60 Million |
| 2022 | -6.86% | -14.62% | 0.22x | 2.09x | €-56.91 Million |
| 2023 | -15.73% | -22.62% | 0.32x | 2.17x | €-74.58 Million |
| 2024 | -12.55% | -14.94% | 0.36x | 2.31x | €-57.08 Million |
| 2025 | -66.05% | -71.13% | 0.29x | 3.25x | €-115.48 Million |
Industry Comparison
This section compares Atrys Health SL's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $47,942,436
- Average return on equity (ROE) among peers: -1.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Atrys Health SL (ATRY) | €147.49 Million | 11.26% | 1.14x | $204.95 Million |
| Biotechnology Assets S.A. (BST) | $6.53 Million | 24.09% | 1.54x | $13.52 Million |
| Oryzon Genomics SA (ORY) | $14.73 Million | -14.66% | 0.95x | $211.33 Million |
| Pharma Mar S.A. (PHM) | $166.90 Million | -21.12% | 0.63x | $1.32 Billion |
| Vytrus Biotech S.A. (VYT) | $3.61 Million | 6.01% | 0.72x | $120.39 Million |
About Atrys Health SL
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through three segments: Diagnosis, Oncology, and Preventive Medicine. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; telediagnosis activities in the fi… Read more